Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies
Source abstract
Abstract
Objective: The aim of this study is to know the biological therapy drugs that are related to adverse events, what dental treatments are associated with the appearance of these events, their severity, and how they are resolved. Study design: Analysis of cases described in the literature on patients undergoing treatment with biological therapies who have developed adverse effects associated with these drugs. Results: Of the 62 articles reviewed, 49 describe 68 cases of MRONJ, most of which appeared in the jaw and received surgical and/or conservative treatment. Conclusions: Biological therapies can potentially develop adverse effects in the oral cavity, so strict monitoring by the dentist is necessary.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Oral and gingival health research · Drug-Induced Adverse Reactions · Bone health and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medicine and Orofacial Surgery, Faculty of Dentistry, Complutense University of Madrid, 28040 Madrid, Spain
References (62)
Show source-provided references
1. Biological therapy and dentistry: A review paper10.1016/j.oooo.2015.07.032 ↗
2. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update10.1016/j.joms.2014.04.031 ↗
3. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline10.1200/JCO.19.01186 ↗
4. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors10.1007/s00520-017-3629-4 ↗
5. Osteonecrosis of the Jaw in a Patient Presenting with Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report10.1016/j.joms.2017.05.016 ↗
6. Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report10.1590/0103-6440201600662 ↗
7. Denosumab osteonecrosis of the mandible: A new entity? A case report10.1016/j.jcms.2012.10.014 ↗
8. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab10.1016/j.jpor.2014.08.001 ↗
9. Aggressive denosumab-related jaw necrosis—A case series10.1038/sj.bdj.2017.573 ↗
10. Osteonecrosis of the Jaw in a patient treated with denosumab and temsirolimus10.18875/2375-7043.4.401 ↗
11. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab10.1016/j.jcms.2013.05.014 ↗
12. Osteonecrosis of the Jaws Unrelated to Bisphosphonate Exposure: A Series of 4 Cases10.1016/j.joms.2012.02.019 ↗
13. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report10.1016/j.jormas.2019.06.009 ↗
14. Rituximab and osteonecrosis of the jaws: Case study10.1016/j.oooo.2013.12.203 ↗
15. Osteonecrosis of the jaw in an anti-resorptive naïve patient taking trastuzumab and pertuzumab: Case report10.1111/adj.12723 ↗
16. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib10.1016/j.ijom.2019.07.010 ↗
17. Sunitinib related osteonecrosis of jaw: A case report10.1016/j.tripleo.2011.06.023 ↗
18. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma10.1016/j.bone.2008.08.132 ↗
19. Osteonecrosis of the jaw related to sunitinib10.1007/s10006-010-0224-y ↗
20. Sunitinib related osteonecrosis of the jaw (SURONJ): A rare occurrence?10.1007/s00238-015-1112-3 ↗
21. Medication-related osteonecrosis of the jaw: Definition and best practice for prevention, diagnosis, and treatment10.1016/j.oooo.2018.09.008 ↗
22. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: Two case reports
23. Oral complications of targeted cancer therapies: A narrative literature review10.1016/j.oraloncology.2011.03.028 ↗
24. Adalimumab-Related Dental Implant Infection10.1016/j.joms.2019.01.033 ↗
25. Tumor Necrosis Factor Inhibition and Invasive Fungal Infections10.1086/430000 ↗
26. Erythema multiforme major following treatment with infliximab10.1016/j.oooo.2012.08.001 ↗
27. Osteonecrosis of the Jaw Related to Bevacizumab10.1200/JCO.2007.15.5424 ↗
28. Bevacizumab-associated osteonecrosis of the jaw10.1093/annonc/mdn653 ↗
29. Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature10.1155/2010/687043 ↗
30. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process10.1136/bcr-2012-007284 ↗
31. Osteonecrosis and the Jaws and Bevacizumab Therapy: A Case Report10.1177/039463201202500328 ↗
32. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents10.2217/fon.13.211 ↗
33. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab10.1007/s10006-012-0379-9 ↗
34. Osteonecrosis of the mandible associated with bevacizumab therapy10.1016/j.oooo.2013.02.001 ↗
35. Bevacizumab-Related Osteneocrosis of the Jaw10.1177/039463200902200429 ↗
36. Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab: Bevacizumab associated osteonecrosis of the jaw10.1111/ors.12153 ↗
37. Osteonecrosis After Administration of Intravitreous Bevacizumab10.1016/j.joms.2011.02.104 ↗
38. Erovigni, F., Gambino, A., Cabras, M., Fasciolo, A., Bianchi, S., Bellini, E., and Fusco, V. (2016). Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. Dent. J., 4.10.3390/dj4040039 ↗
39. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort10.1016/j.oooo.2017.10.010 ↗
40. Osteonecrosis of the jaw related to everolimus: A case report10.1016/j.bjoms.2013.09.008 ↗
41. Osteonecrosis of the jaw associated with everolimus: A case report10.3892/mco.2016.1100 ↗
42. Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient10.1016/j.omsc.2017.03.001 ↗
43. Osteonecrosis of the jaw related to everolimus and bisphosphonate: A unique case report?
44. Osteonecrosis of the jaw associated with ziv-aflibercept10.21037/jgo.2016.05.07 ↗
45. Jaw Osteonecrosisassociated with Aflibercept, Irinotecan and Fluorouracil: Attention to Oral District10.5301/tj.5000405 ↗
46. Medication-related osteonecrosis of the jaw associated with aflibercept10.1016/j.bjoms.2016.11.315 ↗
47. A rare case of osteonecrosis of the jaw related to imatinib10.5125/jkaoms.2017.43.2.120 ↗
48. Osteonecrosis of the jaw a new complication related to Ipilimumab10.1016/j.oraloncology.2015.08.014 ↗
49. Osteonecrosis of the jaw in a patient receiving cabozantinib10.1111/adj.12254 ↗
50. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy10.1093/rheumatology/kes351 ↗
51. Osteonecrosis of the Jaw during Sorafenib Therapy for Hepatocellular Carcinoma10.5301/tj.5000504 ↗
52. Axitinib-related osteonecrosis of the jaw10.1016/j.oooo.2017.08.003 ↗
53. Regorafenib Also Can Cause Osteonecrosis of the Jaw10.1093/jnci/djw002 ↗
54. Preidl, R.H., Ebker, T., Raithel, M., Wehrhan, F., Neukam, F.W., and Stockmann, P. (2014). Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: A case report. BMC Gastroenterol., 14.10.1186/1471-230X-14-6 ↗
55. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?
56. A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab10.12659/AJCR.905355 ↗
57. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis10.3109/08923973.2011.653646 ↗
58. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: Can primary wound closure and a drug holiday really prevent MRONJ?10.1007/s00198-017-4063-7 ↗
59. Dental care for patients taking antiresorptive drugs: A literature review10.5395/rde.2019.44.e42 ↗
60. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention
61. Interventions for managing medication-related osteonecrosis of the jaw
62. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ)